Paroxysmal Nocturnal Hemoglobinuria Treatment Market

Companies Dominating the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Landscape

The global paroxysmal nocturnal hemoglobinuria treatment market is projected for a robust growth curve during the forecast period. Key market players are tying up with local distributors to penetrate new markets and invest in research and development to increase the efficacy of treatment.

Here are some key players in the market:

AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Apellis Pharmaceuticals Inc.
Novartis
Chugai Pharmaceuticals
Roche
UCB
Regeneron Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Report 2037

In the News

In August 2024, Novartis announced accelerated approval by the FDA for Iptacopan (Fabhalta) that is the first complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN). The accelerated approval was granted based on the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study.
In July 2024, the Food and Drug Administration (FDA) of U.S. approved Epysqli to treat PNH. Epysqli is a biosimilar to Soliris and can prevent red blood cell destruction in PNH patients.

Frequently Asked Questions (FAQ)

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market was valued at USD 4.3 billion in 2024 and is positioned to expand at a CAGR of 11.8% during the forecast period, i.e., 2025-2037.

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market registered a valuation of USD 4.3 billion in 2024 and is projected to reach USD 18.5 billion in 2037 at a CAGR of 11.8% during the forecast period, i.e., 2025-2037.

The major players in the market are AstraZeneca, Apellis Pharmaceuticals Inc., Novartis, Chugai Pharmaceuticals, Roche, UCB, Regeneron Pharmaceuticals, and others.

By treatment type, the complement inhibitors segment is projected to dominate the global paroxysmal nocturnal hemoglobinuria treatment with a 72.2% revenue share by 2037 owing to increasing adoption of complement inhibitors in PNH treatment.

North America is projected to hold a dominant revenue share of 47.2% in 2024 due to a robust regulatory ecosystem supporting the approval of new novel therapeutics.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Top Companies and Manufacturers

Companies Dominating the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

Subscribe to Our Newsletters

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Top Companies and Manufacturers

Companies Dominating the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the paroxysmal nocturnal hemoglobinuria (PNH) treatment market?

What is the outlook for the paroxysmal nocturnal hemoglobinuria (PNH) treatment market?

Who are the major players dominating the paroxysmal nocturnal hemoglobinuria (PNH) treatment market?

Which product segment will capture the significant market share for the paroxysmal nocturnal hemoglobinuria (PNH) treatment sector by 2037?

Which region will provide more business opportunities for the growth of the paroxysmal nocturnal hemoglobinuria (PNH) treatment market in the future?